Inhibrx Biosciences (INBX) Revenue (2023 - 2025)

Inhibrx Biosciences (INBX) has 3 years of Revenue data on file, last reported at $1.3 million in Q2 2025.

• Revenue for Q2 2025 came in at $1.3 million, up 1200.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.4 million (down 23.66% YoY), and the FY2025 annual result was $1.3 million, up 550.0% from the prior year.
• Revenue rose to $1.3 million in Q2 2025 per INBX's latest filing, from $100000.0 in the prior quarter.
• Over five years, Revenue peaked at $1.6 million in Q4 2023 and troughed at $30000.0 in Q2 2023.
• A 3-year average of $547166.7 and a median of $109500.0 in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue sank 93.88% in 2024, then surged 1200.0% in 2025.
• A 3-year view of Revenue shows it stood at $1.6 million in 2023, then slumped by 93.88% to $100000.0 in 2024, then surged by 1200.0% to $1.3 million in 2025.
• Business Quant data shows INBX's Revenue at $1.3 million in Q2 2025, $100000.0 in Q4 2024, and $100000.0 in Q2 2024.